| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047056285 |
| P356 | DOI | 10.1186/CC10332 |
| P932 | PMC publication ID | 3387626 |
| P698 | PubMed publication ID | 21798063 |
| P5875 | ResearchGate publication ID | 51529496 |
| P50 | author | Konrad Reinhart | Q1782271 |
| Michael Bauer | Q50638837 | ||
| Jürgen Rödel | Q118189724 | ||
| P2093 | author name string | Katja Menge | |
| Ralf A Claus | |||
| Niels C Riedemann | |||
| Gordon P Otto | |||
| Maik Sossdorf | |||
| P2860 | cites work | Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine | Q22306067 |
| Early goal-directed therapy in the treatment of severe sepsis and septic shock | Q27860596 | ||
| Hydrocortisone therapy for patients with septic shock | Q28264225 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference | Q29618757 | ||
| The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine | Q29618869 | ||
| The pathophysiology and treatment of sepsis | Q29619103 | ||
| Risk factors for negative blood cultures in adult medical inpatients--a retrospective analysis | Q33379958 | ||
| Immunomodulatory therapies in sepsis | Q33901800 | ||
| Cell death | Q34019760 | ||
| Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. | Q34480866 | ||
| Novel strategies for the treatment of sepsis | Q35118750 | ||
| Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? | Q35124230 | ||
| Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis | Q39984946 | ||
| Immunotherapy for sepsis--a new approach against an ancient foe. | Q42802907 | ||
| A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. | Q43711066 | ||
| Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. | Q52909875 | ||
| Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. | Q53001328 | ||
| Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. | Q53753081 | ||
| Early assessment of leukocyte alterations at diagnosis of septic shock. | Q54437566 | ||
| Increasing evidence that the risks of rhAPC may outweigh its benefits. | Q55043389 | ||
| Sir Isaac Newton, sepsis, SIRS, and CARS | Q71171155 | ||
| Unraveling severe sepsis: why did OPTIMIST fail and what's next? | Q73635896 | ||
| Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group | Q77292359 | ||
| The lingering consequences of sepsis: a hidden public health disaster? | Q82068394 | ||
| P433 | issue | 4 | |
| P921 | main subject | sepsis | Q183134 |
| P304 | page(s) | R183 | |
| P577 | publication date | 2011-07-28 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | The late phase of sepsis is characterized by an increased microbiological burden and death rate | |
| P478 | volume | 15 |
| Q41574040 | A Murine Model of Persistent Inflammation, Immune Suppression, and Catabolism Syndrome |
| Q26774775 | A Review of GM-CSF Therapy in Sepsis |
| Q38698676 | Advanced glycation endproducts induce self- and cross-tolerance in monocytes. |
| Q35079753 | An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation |
| Q34762245 | An integrated transcriptome and expressed variant analysis of sepsis survival and death |
| Q89575016 | Antibody-modified conduits for highly selective cytokine elimination from blood |
| Q58777471 | Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer |
| Q34417352 | Assessing the immune status of critically ill trauma patients by flow cytometry |
| Q49751937 | Autophagy: A Potential Therapeutic Target for Reversing Sepsis-Induced Immunosuppression |
| Q40763516 | BTLA as a biomarker and mediator of sepsis-induced immunosuppression |
| Q47990314 | Balance Between the Proinflammatory and Anti-Inflammatory Immune Responses with Blood Transfusion in Sepsis. |
| Q36829883 | Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis |
| Q26785255 | Biomarkers for Sepsis: What Is and What Might Be? |
| Q41113797 | Bugs, genes, and the intensive care unit |
| Q26796132 | CD1d- and MR1-Restricted T Cells in Sepsis |
| Q94453338 | Characterization of human peripheral blood γδ T cells in patients with sepsis |
| Q38796965 | Chronic Critical Illness from Sepsis Is Associated with an Enhanced TCR Response |
| Q36252387 | Collapse of the Microbiome, Emergence of the Pathobiome, and the Immunopathology of Sepsis |
| Q40503612 | Combining Biomarkers with EMR Data to Identify Patients in Different Phases of Sepsis. |
| Q47102661 | Diabetes and Sepsis: Risk, Recurrence, and Ruination |
| Q40659436 | Diagnostic value of elevated serum miRNA-143 levels in sepsis |
| Q64096192 | Early and dynamic alterations of Th2/Th1 in previously immunocompetent patients with community-acquired severe sepsis: a prospective observational study |
| Q93172729 | Epigenetic and metabolic programming of innate immunity in sepsis |
| Q41620454 | Epigenetic regulation in sepsis : current state of knowledge |
| Q33822199 | Evaluation of Toll-like, chemokine, and integrin receptors on monocytes and neutrophils from peripheral blood of septic patients and their correlation with clinical outcomes. |
| Q40060679 | Evidence for Persistent Immune Suppression in Patients WHO Develop Chronic Critical Illness After Sepsis |
| Q92560672 | Frontline Science: Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst |
| Q39103864 | Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock |
| Q50669666 | Frontline Science: Myeloid cell-specific deletion of Cebpb decreases sepsis-induced immunosuppression in mice. |
| Q35343353 | Gamma-irradiated bacille Calmette-Guérin vaccination does not modulate the innate immune response during experimental human endotoxemia in adult males |
| Q38673357 | Glucocorticoid-induced leucine zipper (GILZ) in immuno suppression: master regulator or bystander? |
| Q89209470 | Group 2 Innate Lymphoid Cells (ILC2s) Are Key Mediators of the Inflammatory Response in Polymicrobial Sepsis |
| Q40105688 | Hemoadsorption corrects hyperresistinemia and restores anti-bacterial neutrophil function. |
| Q90346463 | IL-10 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development |
| Q40265668 | IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. |
| Q92225661 | Identifying Sepsis Subtypes from Routine Clinical Data |
| Q97530822 | Immune-mediated approaches against COVID-19 |
| Q39667843 | Immunology. Getting sepsis therapy right |
| Q29994669 | Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy |
| Q38152236 | Immunopathogenesis of abdominal sepsis |
| Q27320494 | Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function |
| Q37233354 | Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach |
| Q22306306 | Immunotherapy for the Adjunctive Treatment of Sepsis: From Immunosuppression to Immunostimulation. Time for a Paradigm Change? |
| Q38836832 | Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression |
| Q58744056 | Impact of human sepsis on CCCTC-binding factor associated monocyte transcriptional response of Major Histocompatibility Complex II components |
| Q64267206 | Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine |
| Q37479521 | Incidence, risk factors and impact on outcomes of secondary infection in patients with septic shock: an 8-year retrospective study. |
| Q58727541 | Increased mortality in CD43-deficient mice during sepsis |
| Q100487184 | Inducing Experimental Polymicrobial Sepsis by Cecal Ligation and Puncture |
| Q37066067 | Induction of Siglec-1 by Endotoxin Tolerance Suppresses the Innate Immune Response by Promoting TGF-β1 Production |
| Q59066703 | Induction of innate immune memory via microRNA targeting of chromatin remodelling factors |
| Q54123125 | Inhibition of MicroRNA-23b Attenuates Immunosuppression in Late Sepsis through NIK, TRAF1 and XIAP. |
| Q55653469 | Innate and adaptive immune dysregulation in critically ill ICU patients. |
| Q38957840 | Interleukin-33 in health and disease |
| Q27691996 | Is boosting the immune system in sepsis appropriate? |
| Q41489395 | Is nosocomial infection really the major cause of death in sepsis? |
| Q36240643 | LPS-induced modules of co-expressed genes in equine peripheral blood mononuclear cells |
| Q26786504 | Lactate kinetics in sepsis and septic shock: a review of the literature and rationale for further research |
| Q47114602 | MiR-6835 promoted LPS-induced inflammation of HUVECs associated with the interaction between TLR-4 and AdipoR1 in lipid rafts. |
| Q41471053 | MicroRNA-155 attenuates late sepsis-induced cardiac dysfunction through JNK and β-arrestin 2. |
| Q36360483 | Modulatory Effects of Astragalus Polysaccharides on T-Cell Polarization in Mice with Polymicrobial Sepsis. |
| Q34515768 | Modulatory role of vitamin A on the Candida albicans-induced immune response in human monocytes |
| Q57117292 | Molecular signatures of liver dysfunction are distinct in fungal and bacterial infections in mice |
| Q54248941 | Mortality outcomes based on ED qSOFA score and HIV status in a developing low income country. |
| Q64094878 | Myeloid-Derived Suppressor Cells in Sepsis |
| Q36356983 | NFI-A disrupts myeloid cell differentiation and maturation in septic mice |
| Q39154403 | Neutrophil dysregulation during sepsis: an overview and update |
| Q34303687 | New approaches to sepsis: molecular diagnostics and biomarkers. |
| Q40268058 | Overexpression of HO-1 Contributes to Sepsis-Induced Immunosuppression by Modulating the Th1/Th2 Balance and Regulatory T-Cell Function |
| Q58764867 | Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis |
| Q47755022 | PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1α. |
| Q38830793 | Pathogenic, immunologic, and clinical aspects of sepsis - update 2016. |
| Q90703154 | Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis |
| Q90074305 | Pharmacokinetics, Pharmacodynamics and Safety of Nivolumab in Patients With Sepsis-induced immunosuppression: A multicenter, open-label phase 1/2 study |
| Q59138110 | Polymicrobial Sepsis Chronic Immunoparalysis Is Defined by Diminished Ag-Specific T Cell-Dependent B Cell Responses |
| Q99237747 | Polymicrobial Sepsis Impairs Antigen-Specific Memory CD4 T Cell-Mediated Immunity |
| Q50133355 | Polymicrobial sepsis and non-specific immunization induce adaptive immunosuppression to a similar degree. |
| Q47102338 | Potential Immunotherapeutics for Immunosuppression in Sepsis |
| Q39615420 | Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis |
| Q57160595 | Precision Immunotherapy for Sepsis |
| Q33753665 | Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis |
| Q35100021 | Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. |
| Q36574855 | Prognostic utility of plasma lactate measured between 24 and 48 h after initiation of early goal-directed therapy in the management of sepsis, severe sepsis, and septic shock |
| Q29994668 | Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
| Q33740315 | Reactivation of multiple viruses in patients with sepsis |
| Q54222088 | Recent advances in nanomedicine for sepsis treatment. |
| Q36998138 | Removal of regulatory T cells prevents secondary chronic infection but increases the mortality of subsequent sub-acute infection in sepsis mice. |
| Q54331733 | Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. |
| Q36424717 | Reversal of neutrophil-to-lymphocyte count ratio in early versus late death from septic shock |
| Q85639992 | Screening for bacteremia in sepsis and renal failure using hemofilters for renal replacement therapy |
| Q59136322 | Sepsis and Nosocomial Infection: Patient Characteristics, Mechanisms, and Modulation |
| Q59708886 | Sepsis and septic shock |
| Q58571845 | Sepsis in mechanically ventilated patients with spinal cord injury: a retrospective analysis |
| Q38148132 | Sepsis induced immunosuppression: Implications for secondary infections and complications |
| Q64233869 | Sepsis induces long-lasting impairments in CD4+ T-cell responses despite rapid numerical recovery of T-lymphocyte populations |
| Q38541110 | Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy |
| Q33828888 | Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy |
| Q36774624 | Sepsis-induced long-term immune paralysis--results of a descriptive, explorative study |
| Q91692831 | Sepsis: Inflammation Is a Necessary Evil |
| Q64112480 | Sepsis: evolving concepts and challenges |
| Q34612152 | Serum procalcitonin level and SOFA score at discharge from the intensive care unit predict post-intensive care unit mortality: a prospective study |
| Q36097432 | Sirtuin-2 Regulates Sepsis Inflammation in ob/ob Mice |
| Q58742374 | Sirtuins and Immuno-Metabolism of Sepsis |
| Q36812451 | Stimulated Whole Blood Cytokine Release as a Biomarker of Immunosuppression in the Critically Ill: The Need for a Standardized Methodology |
| Q37719478 | Suppression of T Cell Autophagy Results in Decreased Viability and Function of T Cells Through Accelerated Apoptosis in a Murine Sepsis Model |
| Q51071957 | T helper type 2-polarized invariant natural killer T cells reduce disease severity in acute intra-abdominal sepsis. |
| Q33723244 | T-cell Co-inhibitory Molecules in Sepsis-induced Immunosuppression: From Bench to Bedside |
| Q58801821 | TNFR1 Signaling Contributes to T Cell Anergy During Sepsis |
| Q47150101 | Targeting Immune Cell Checkpoints during Sepsis |
| Q44655068 | Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. |
| Q33749945 | Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis |
| Q57477163 | The CTLA-4 rs231775 GG genotype is associated with favorable 90-day survival in Caucasian patients with sepsis |
| Q55419461 | The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3. |
| Q39010121 | The Host Response in Patients with Sepsis Developing Intensive Care Unit-acquired Secondary Infections |
| Q27342598 | The Macrophage Mediates the Renoprotective Effects of Endotoxin Preconditioning |
| Q91711995 | The Role of PD-1 in Acute and Chronic Infection |
| Q35919596 | The Shift of an Intestinal "Microbiome" to a "Pathobiome" Governs the Course and Outcome of Sepsis Following Surgical Injury |
| Q37563023 | The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? |
| Q58726835 | The clinical importance of a cytokine network in the acute phase of sepsis |
| Q38991057 | The immune system's role in sepsis progression, resolution, and long-term outcome |
| Q37686624 | The new normal: immunomodulatory agents against sepsis immune suppression |
| Q92374177 | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
| Q92615815 | Time and sex dependency of hemodynamic, renal, and survivability effects of endotoxemia in rats |
| Q64084951 | Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis |
| Q34543367 | Toll-like receptor 4 is essential to preserving cardiac function and survival in low-grade polymicrobial sepsis. |
| Q42331372 | Towards precision medicine for sepsis patients. |
| Q92453856 | Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis |
| Q41835917 | Why a second look might be worth it: immuno-modulatory therapies in the critically ill patient |
Search more.